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PCardiac Effects of Diabetes
Myocardial Steatosis Is an Independent Predictor
of Diastolic Dysfunction in Type 2 Diabetes Mellitus
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Objectives The purpose of this study was to compare myocardial triglyceride content and function between patients with
uncomplicated type 2 diabetes mellitus (T2DM) and healthy subjects within the same range of age and body
mass index (BMI), and to study the associations between myocardial triglyceride content and function.
Background T2DM is a major risk factor for cardiovascular disease. Increasing evidence is emerging that lipid oversupply to
cardiomyocytes plays a role in the development of diabetic cardiomyopathy, by causing lipotoxic injury and myo-
cardial steatosis.
Methods Myocardial triglyceride content and myocardial function were measured in 38 T2DM patients and 28 healthy
volunteers in the same range of age and BMI by proton magnetic resonance (MR) spectroscopy and MR imag-
ing, respectively. Myocardial triglyceride content was calculated as a percentage relative to the signal of myocar-
dial water.
Results Myocardial triglyceride content was significantly higher in T2DM patients compared with healthy volunteers
(0.96  0.07% vs. 0.65  0.05%, p  0.05). Systolic function did not significantly differ between both groups.
Indexes of diastolic function, including the ratio of maximal left ventricular early peak filling rate and the maxi-
mal left ventricular atrial peak filling rate (E/A) and E peak deceleration, were significantly impaired in T2DM
compared with those in healthy subjects (1.08  0.04 ml/s2  103 vs. 1.24  0.06 ml/s2  103 and 3.6 
0.2 ml/s2  103 vs. 4.4  0.3 ml/s2  103, respectively, p  0.05). Multivariable analysis indicated that
myocardial triglyceride content was associated with E/A and E peak deceleration, independently of diabetic
state, age, BMI, heart rate, visceral fat, and diastolic blood pressure.
Conclusions Myocardial triglyceride content is increased in uncomplicated T2DM and is associated with impaired left ventric-
ular diastolic function, independently of age, BMI, heart rate, visceral fat, and diastolic blood pressure. (J Am
Coll Cardiol 2008;52:1793–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.062F
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pype 2 diabetes mellitus (T2DM) is a major risk factor for
ardiovascular disease and early death (1,2). The pathophys-
ology of nonischemic diabetic cardiomyopathy is complex,
nd the exact mechanisms of disease remain partly unknown
2). Increasing evidence is emerging that lipid oversupply to
ardiomyocytes, which may lead to lipotoxic injury, plays a
ole in the development of diabetic cardiomyopathy (3–5).
ncreased fatty acid (FA) fluxes arising from the dispropor-
ionate amount of insulin resistant (visceral) adipose tissue
ead to excessive FA delivery and uptake in the heart. This
rom the *Department of Endocrinology, VU University Medical Center, Amsterdam,
he Netherlands; and the Departments of †Radiology, ‡Endocrinology, and §Cardi-
logy, Leiden University Medical Center, Leiden, the Netherlands. The first two
uthors contributed equally to this work. Steven E. Nissen, MD, MACC, served as
uest Editor for this article.c
Manuscript received May 26, 2008; revised manuscript received July 25, 2008,
ccepted July 30, 2008.A uptake exceeds the oxidizing requirements of the organ,
iving rise to fatty acyl-CoA esters, diacylglycerol, and
eramide as intermediates (5). Increasing evidence exists
hat accumulation of these FA intermediates causes mito-
hondrial dysfunction and reactive oxygen species, giving
ise either directly to cell damage and apoptosis or indirectly
hrough the induction of inflammatory cascades, which
eads to myocardial dysfunction (6–9). In animal models,
See page 1800
ntisteatotic treatment with thiazolidinediones reduced
yocardial triglyceride accumulation and ceramide content,
nd prevented myocardial dysfunction (7). Recently, it has
een demonstrated in a heterogeneous group of T2DM
atients that myocardial triglyceride content was increased
ompared with that in young, lean, healthy control subjects
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Myocardial Steatosis and Function in Diabetes November 25, 2008:1793–9(10). However, direct correla-
tions between myocardial triglyc-
eride accumulation and heart
function could not be estab-
lished. To investigate the net
contribution of T2DM to myo-
cardial triglyceride accumulation
and the associated functional
consequences, it is essential to
select controls within the same
range of age and body mass index
(BMI). In addition, to investi-
gate the association between
myocardial triglyceride accumu-
lation and heart function, under-
lying ischemic heart disease
should be excluded.
Left ventricular (LV) diastolic
function can be assessed using
flow velocity encoded magnetic
resonance imaging (MRI). Using
this technique, myocardial dia-
stolic functional parameters have
een shown to associate with myocardial triglyceride accu-
ulation in healthy volunteers (11). Furthermore, in ex-
lanted hearts of obese and T2DM patients with end-stage
eart failure, lipid staining was a common finding (4).
In addition to myocardial accumulation of triglycerides,
2DM is associated with increased visceral adipose tissue,
hich associates with elevations of circulating plasma tri-
lycerides and nonesterified fatty acid (NEFA) levels, and
hus contributes to lipid overexposure to nonadipose tissue
ompartments.
Therefore, the purpose of the present study was to
ompare myocardial and hepatic triglyceride content and
yocardial function between patients with uncomplicated
2DM and healthy subjects within the same range of age
nd BMI and to study the associations between myocardial
riglyceride accumulation and heart function.
ethods
ubjects. Forty-one male T2DM patients were included in
his study, which was approved by the local ethics commit-
ee. Hormonal status or use of contraceptives may affect
ipid metabolism in women. Plasma estrogen levels influ-
nce lipid metabolism (including plasma lipid levels, adipose
issue), and gender differences in expression of certain cell
urface receptors/transporters of fatty acids have been re-
orted (12,13). Therefore, we decided to exclude women to
void possible confounding influences of fluctuation in lipid
etabolism in women on hepatic and myocardial triglycer-
de accumulation. All participants signed informed consent.
atients were recruited by advertisements in local newspa-
ers according to the following inclusion criteria: 1) age 45
Abbreviations
and Acronyms
A  atrial contraction
BMI  body mass index
E  early diastolic filling
phase
E/A  ratio of maximal left
ventricular early peak filling
rate and the maximal left
ventricular atrial peak
filling rate
E/Ea  estimation of left
ventricular filling pressures
LV  left
ventricle/ventricular
MR  magnetic resonance
MRI  magnetic resonance
imaging
(NE)FA  (nonesterified)
fatty acids
T2DM  type 2 diabetes
mellituso 65 years; 2) T2DM diagnosed according to World wealth Organization criteria (14) and treated with sulfonyl-
rea derivates in stable doses; 3) glycated hemoglobin below
.5%; and 4) sitting blood pressure 150/85 mm Hg, with
r without antihypertensive drugs. Exclusion criteria in-
luded impaired hepatic function or a history of liver
isease; substance abuse; known cardiovascular disease or
iabetes-related complications, including proliferative reti-
opathy; autonomic neuropathy, as excluded by Ewing’s
ests (15); microalbuminuria, as excluded by measurements
f albumin/creatinine ratio in a urine sample; and all
ontraindications for MRI. Furthermore, to avoid interfer-
nce with the main study parameters, patients on lipid
owering therapy (such as statins, fibrates) were excluded.
ost importantly, however, myocardial ischemia was
xcluded by means of high-dose dobutamine stress
chocardiography.
Thirty healthy male control subjects within the same
ange of age (45 to 65 years) and BMI (25 to 32 kg/m2) as
he patient group were recruited by advertisements in the
ocal newspapers. Subjects were included when they fulfilled
he following criteria: no known acute or chronic disease
ased on history and physical examination and standard
aboratory tests (blood counts, fasting blood glucose, lipids,
erum creatinine, liver enzymes, and electrocardiogram).
xclusion criteria included chronic use of any drug, sub-
tance abuse, hypertension, and impaired glucose tolerance
as excluded by a 75-g oral glucose tolerance test) (16).
agnetic resonance (MR) spectroscopy. All subjects un-
erwent MR scanning in the morning for assessment of
ctopic triglyceride content and heart function after an
vernight fast and after blood sampling. All MR studies
ere performed with the use of a 1.5-T whole-body MR
canner (Gyroscan ACS/NT15, Philips, Best, the Nether-
ands) with subjects in the supine position at rest.
Myocardial 1H-MR spectra were obtained as described
reviously (17). Briefly, the body coil was used for radiofre-
uency transmission and a 17-cm diameter circular surface
oil was used for signal reception. An 8-ml voxel was
ositioned in the interventricular septum. Spectroscopic
ata acquisition was double triggered using electrocardio-
raphic triggering and respiratory navigator echoes to min-
mize breathing influences (17). Water suppressed spectra
ere acquired for detection of the triglyceride signals at end
ystole, with an echo time of 26 ms and a repetition time of
t least 3,000 ms, and 1,024 data points were collected using
1,000-Hz spectral width and averaged over 128 acquisi-
ions. Without changing any parameter, spectra without
ater suppression with a repetition time of 10 s and 4
verages were obtained from the same voxel, to be used as an
nternal standard.
1H-MR spectroscopy of the liver was performed with an
-ml voxel positioned in the liver, avoiding gross vascular
tructures and adipose tissue depots. Spectra were obtained
sing the same parameters as described for myocardial
H-MR spectroscopy. Only 64 averages were collected with
ater suppression. All 1H-MR spectroscopic data were
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November 25, 2008:1793–9 Myocardial Steatosis and Function in Diabetestted using Java-based MR user interface software (jMRUI
ersion 2.2, developed by A. van den Boogaart, Katholieke
niversiteit Leuven, Leuven, Belgium) (18) as described
reviously (17). Myocardial and hepatic triglyceride con-
ent was calculated as a percentage relative to water as
signal amplitude of triglyceride)/(signal amplitude of
ater)  100.
R imaging. All images were analyzed quantitatively using
edicated software (FLOW or MASS, Medis, Leiden, the
etherlands). The entire heart was imaged in short-axis
rientation using electrocardiographically gated breath-
olds with a sensitivity encoding balanced turbo-field echo
equence. Imaging parameters included the following: echo
ime  1.7 ms, repetition time  3.4 ms, flip-angle  35°,
lice thickness  10 mm with a gap of 0 mm, field of
iew  400  400 mm, reconstructed matrix size  256 
56. LV ejection fraction was assessed for the determination
f LV systolic function. In addition, LV mass/(end-
iastolic) volume ratio was calculated
An electrocardiographically gated gradient-echo sequence
ith velocity encoding was performed to measure blood flow
cross the mitral valve for determination of LV diastolic
unction. Imaging parameters included the following: echo
ime  5 ms, repetition time  14 ms, flip-angle  20°, slice
hickness 8 mm, field of view 350 350 mm, matrix size
256  256, velocity encoding gradient  100 cm/s, scan
ercentage  80%. The resulting biphasic diastolic inflow
attern consists of 2 peaks, representing the early filling phase
nd the atrial contraction. Analysis of the early filling phase
nd the atrial contraction was performed by calculating their
eak filling rates and ratio of the peak filling rates (E/A).
urthermore, the peak deceleration gradient of the early filling
hase (E deceleration peak) was calculated automatically. In
ddition, an estimation of LV filling pressures (E/Ea) was
ssessed as described earlier (19). During MRI, blood pressure
nd heart rate were measured.
Abdominal visceral fat depots were quantified by MRI
20). A turbo spin echo imaging protocol was used and
maging parameters included the following: echo time  11
s, repetition time  168 ms, flip angle  90°, slice
hickness  10 mm. Three consecutive transverse images
ere obtained during 1 breath hold, with the middle image at
level just above the fifth lumbar vertebra. The volumes of the
isceral fat depots of all slices were calculated by converting the
umber of pixels to square centimeters multiplied by the slice
hickness. The total volume of the fat depots was calculated by
umming the volumes of all three slices.
ssays. All samples were analyzed at 1 certified central
aboratory (Amsterdam, the Netherlands). Plasma glucose
as measured using a hexokinase-based technique (Roche
iagnostics, Mannheim, Germany); glycated hemoglobin
as determined by high-performance liquid chromatogra-
hy (Menarini Diagnostics, Florence, Italy; reference values:
.3% to 6.1%). Plasma total cholesterol, high-density li-
oprotein cholesterol, and triglycerides were determined
sing enzymatic colorimetric methods (Modular, Hitachi,
sapan). Low-density lipoprotein cholesterol was calculated
sing Friedewald’s formula. Insulin was measured by an
mmunoradiometric assay (Bayer Diagnostics, Mijdrecht,
he Netherlands). NEFAs were assessed using enzyme-
inked immunoabsorbent assay (WAKO Chemicals, Neuss,
ermany).
tatistical analysis. Statistical analysis was performed us-
ng SPSS for Windows version 12.0 (SPSS Inc., Chicago,
llinois). Data are expressed as mean  standard error when
ormally distributed; data not normally distributed are
xpressed as median (interquartile range). Non-normally
istributed data were log-transformed, and unpaired t tests
or, when appropriate, nonparametric tests) were used for
omparisons. To detect determinants of myocardial triglycer-
de content and LV function, univariate and multivariable
inear regression analyses were performed. Values of p  0.05
ere considered statistically significant.
esults
aseline characteristics of patients and healthy subjects are
isplayed in Table 1. The MR scan protocol could not
uccessfully be completed due to technical constraints in 3
atients and in 2 healthy subjects. Therefore, data obtained
rom 38 patients and 28 healthy subjects were used for
nalysis. Mean systolic blood pressure in both groups was
ell within the normal range, although it was higher in
atients than in controls (127  2 mm Hg vs. 116  2 mm
g, p  0.05). Although autonomic neuropathy was
bsent, documented by Ewing’s tests in the patients, their
esting heart rate was increased relative to that in controls
median [interquartile range]: 65 [62 to 72] beats/min vs. 59
52 to 63] beats/min, p  0.05).
yocardial and hepatic triglyceride content. Myocardial
riglyceride content was significantly higher in patients with
2DM compared with healthy volunteers (0.96  0.07% vs.
linical and Biochemical Characteristics
Table 1 Clinical and Biochemical Characteristics
Healthy Subjects
(n  28)
Patients With T2DM
(n  38)
Age (yrs) 54 1 57 1
Body mass index (kg/m2) 26.9 0.5 28.1 0.6
Systolic blood pressure (mm Hg) 116 2 127 2*
Diastolic blood pressure (mm Hg) 73 2 76 1
Heart rate (beats/min) 59 (52–63) 65 (62–72)*
Plasma glucose (mmol/l) 5.3 0.1 9.1 0.3*
Plasma insulin (pmol/l) 35 (24–51) 55 (35–100)*
Glycated hemoglobin (%) 5.33 0.05 7.21 0.17*
Plasma triglycerides (mmol/l) 1.0 (0.8–1.3) 1.6 (1.1–2.8)*
Nonesterified fatty acids (mmol/l) 0.45 0.04 0.49 0.03
High-density lipoprotein cholesterol
(mmol/l)
1.39 0.06 1.09 0.04*
Low-density lipoprotein cholesterol
(mmol/l)
3.3 (3.0–3.7) 2.9 (2.6–3.4)*
Total cholesterol (mmol/l) 5.29 0.14 5.00 0.13
ata are mean standard error or median (interquartile range). *p 0.05 compared with healthy
ubjects.
T2DM  type 2 diabetes mellitus.
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Myocardial Steatosis and Function in Diabetes November 25, 2008:1793–9.65 0.05%), as was hepatic triglyceride content (8.6% [2.7%
o 24.3%] vs. 2.2% [1.2% to 3.8%], p 0.05) (Table 2, Fig. 1).
yocardial triglyceride content showed significant univariate
orrelations with age, visceral adipose tissue volume, plasma
riglycerides, plasma high-density lipoprotein cholesterol,
lasma glucose, plasma insulin concentrations, and hepatic
riglyceride content (Pearson r 0.28, 0.36, 0.37,0.39, 0.45,
.30, and 0.37, respectively, p  0.05), but not with BMI, in
ll study subjects pooled. Visceral adipose tissue volume,
lasma high-density lipoprotein cholesterol and glucose con-
entrations, as well as hepatic triglyceride content remained
ignificantly correlated to myocardial triglyceride content after
djustment for diabetic state; the association between plasma
riglyceride levels and myocardial triglyceride content showed
orderline significance when adjusted for diabetic state
p  0.051).
ssociation between myocardial steatosis and myocardial
unction. Differences in cardiovascular function between
2DM patients and healthy volunteers are displayed in
agnetic Resonance Study Parameters
Table 2 Magnetic Resonance Study Parameters
Healthy Subjects Patients With T2DM
Myocardial triglyceride content (%) 0.65 0.05 0.96 0.07*
Hepatic triglyceride content (%) 2.2 (1.2–3.8) 38.6 (2.7–24.3)*
Visceral fat (ml) 284 24 420 31*
LV mass (g) 108 5 105 3
LV mass/volume ratio (g/ml) 0.09 0.02 0.11 0.02*
LV ejection fraction (%) 58 1 60 1
E peak filling rate (ml/s) 490 21 426 14*
E peak deceleration (ml/s2  103) 4.4 0.3 3.6 0.2*
A peak filling rate (ml/s) 402 9 401 10
E/A 1.24 0.06 1.08 0.04*
E/Ea 9.1 0.6 10.0 0.7
ata are mean standard error or median (interquartile range). *p 0.05 compared with healthy
ubjects.
A  atrial contraction; E  early diastolic filling phase; E/A  ratio of maximal left ventricular
arly peak filling rate and the maximal left ventricular atrial peak filling rate; E/Ea estimation of
eft ventricular filling pressures; LV  left ventricular; LV mass/volume ratio  left ventricular
ass/left ventricular end-diastolic volume; T2DM  type 2 diabetes mellitus.
Figure 1 Myocardial and Hepatic Triglyceride Content in Patien
Bar graphs show increased myocardial and hepatic triglyceride content in diabetic
Bars represent mean  standard error for myocardial triglycerides and median able 2. The LV diastolic parameters were significantly
mpaired in T2DM patients, but LV systolic function was
ot significantly different between healthy subjects and
2DM patients (ejection fraction  58  1% vs. 60  1%,
 0.05).
E/A and E peak deceleration were used as parameters of
V diastolic function for further analysis. Table 3 lists
earson correlations of E/A and the E deceleration peak
ith several parameters in all study subjects and shows that
oth parameters were significantly inversely correlated to
ge, heart rate, blood pressure, plasma glucose levels, and
yocardial triglyceride content (p  0.05) (Fig. 2).
Multivariable analysis was performed in all subjects to
tudy the association between diastolic function and myo-
ardial triglyceride content. To this purpose, E/A was
ntered as a dependent variable, and subsequently, myocar-
ial triglyceride content, the presence of T2DM, age, heart
ate, and diastolic blood pressure were entered into the
odel as independent variables (Table 4). Diabetic state had
o effect on the association between E/A and myocardial
riglyceride content. Furthermore, adjustment for age, heart
ate, and diastolic blood pressure, which were all signifi-
antly correlated to E/A, had no effect on the association
etween E/A and myocardial triglyceride content. Identical
nalyses were performed with E peak deceleration as inde-
endent variable. This analysis indicated myocardial triglyc-
ride content associated with E peak deceleration, indepen-
ently of diabetic state, age, heart rate, and diastolic blood
ressure.
iscussion
n this study, we showed that accumulation of myocardial
riglycerides in T2DM patients is associated with LV
iastolic dysfunction, independently of age, BMI, heart rate,
isceral fat, and diastolic blood pressure.
We were able to extend the findings in previous studies
howing myocardial steatosis in T2DM patients (4,10).
d Controls
ts as compared with healthy control subjects.
artile range for hepatic triglycerides. *p  0.05.ts an
patien
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November 25, 2008:1793–9 Myocardial Steatosis and Function in DiabetescGavock et al. (10) demonstrated that excessive triglyc-
ride accumulation in human cardiomyocytes occurs early in
he natural history of T2DM. In their study, a heteroge-
eous group of T2DM patients showed increased myocar-
ial triglyceride content compared with healthy subjects.
he use of insulin (a well-known lipogenic agent, which
ight have increased myocardial triglyceride levels) by the
2DM patients, and differences in age and BMI between
he two groups could have influenced their observations. In
ddition, the occurrence of silent ischemia, which can be
resent in up to 22% of asymptomatic T2DM patients with
normal electrocardiogram (21), could influence accumu-
ation of triglycerides in the reversibly injured myocardium
uring reperfusion (22,23). Therefore, in the present study,
e used controls of the same sex and within the same range
f age and BMI as patients, and included only T2DM
atients with normal dobutamine stress echocardiography
Myocardial Triglyceride Content (%)
E
/ A
0.0
1.0
0.5
0.5 1.0 1.5 2.0 2.5 3.00.0
1.5
2.0
2.5
Type 2 Diabetes Mellitus
Healthy Subjects
r=-0.42, p < 0.05
Figure 2 Correlations Between Myocardial Triglyceride Content
Increased myocardial triglyceride content is significantly associated with decreased
E  early diastolic filling phase, E/A  ratio of maximal left ventricular early peak
nivariate Correlations Betweeniastolic Function and Anthropometricd Bio hemical M rkers and Fat Compartments
Table 3
Univariate Correlations Between
Diastolic Function and Anthropometric
and Biochemical Markers and Fat Compartments
E/A
E Peak
Deceleration
(ml/s2  103)
Age (yrs) 0.58* 0.44*
Body mass index (kg/m2) 0.25* 0.18
Log heart rate (beats/min) 0.36* 0.36*
Systolic blood pressure (mm Hg) 0.26* 0.24
Diastolic blood pressure (mm Hg) 0.41* 0.45*
LV mass/volume ratio (g/ml) 0.35* 0.46*
Plasma glucose (mmol/l) 0.32* 0.34*
Log plasma triglyceride (mmol/l) 0.01 0.05
Nonesterified fatty acids (mmol/l) 0.01 0.09
High-density lipoprotein cholesterol (mmol/l) 0.21 0.28*
Visceral fat (ml) 0.31* 0.20
Hepatic triglyceride content (%) 0.30* 0.21
Myocardial triglyceride content (%) 0.42* 0.40*
alues are Pearson r. *p  0.05.
Abbreviations as in Table 2.o control for reversible ischemia. By using these well-
efined groups we could confirm that myocardial triglycer-
de content in T2DM patients is significantly elevated in
omparison with healthy volunteers, independently of age or
MI.
In our study, diabetic patients had higher plasma triglyc-
ride levels and showed significantly lower levels of high-
ensity lipoprotein cholesterol compared with control sub-
ects. Interestingly, plasma triglyceride concentrations were
ositively associated with myocardial triglyceride content. In
ddition, we found an inverse correlation between myocar-
ial triglyceride content and high-density lipoprotein cho-
esterol levels, adjusted for diabetic state. These data are in
ine with earlier observations demonstrating that increased
erum triglyceride and decreased serum high-density li-
oprotein cholesterol concentrations correlate with lipid
ontent in skeletal muscle in patients with human immu-
odeficiency virus–lipodystrophy (24). High-density li-
oprotein cholesterol is considered an important mediator
f reverse cholesterol transport, a process that involves the
ransfer and uptake of free cholesterol from the peripheral
issues, with subsequent delivery to the liver, where it can be
liminated. Artificial elevation of high-density lipoprotein
n cholesterol-fed rabbits induced the regression of early
ortic fatty streaks (25). Based on our results, we hypothe-
ize that reverse cholesterol transport might also play a role
n protecting the heart from accumulating lipids.
In the present study, we are the first to demonstrate that
yocardial triglyceride accumulation in patients with un-
omplicated T2DM is associated with LV diastolic dysfunc-
ion, independently of age, BMI, blood pressure, and heart
ate. Neutral triglycerides are probably inert and harmless to
ells and may initially even provide a protective buffer by
iverting NEFA from deleterious pathways (26). Eventu-
lly, however, excessive triglyceride stores enter a continuous
ycle between hydrolysis and fatty acid re-esterification,
ielding cardiotoxic intermediates, such as ceramide and
Myocardial Triglyceride Content (%)
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Myocardial Steatosis and Function in Diabetes November 25, 2008:1793–9iacylglycerol, which seems to be an important route leading
o myocardial dysfunction, at least in animal models (7,27).
In the present study, LV ejection fraction was not
ifferent between patients and healthy control subjects and
as dissociated from myocardial triglyceride content. We
xcluded patients with myocardial ischemia and contractile
bnormalities, using dobutamine stress echocardiography,
ut microvascular disease cannot be ruled out. Previous
xperimental studies (28) have shown decreased contractility
nd diastolic function contemporary with hypertrophy and
oncentric remodeling. In our patient population with
ncomplicated diabetes mellitus, cardiac mass was not
ifferent from that in healthy volunteers. LV mass/volume
atio was increased in T2DM patients, indicating mild
oncentric remodeling (29). Therefore, LV mass/volume
atio was included in the multivariable analysis, but had no
nfluence on the independent relationship between myocar-
ial triglyceride content and diastolic function.
Based on these findings, we hypothesize that there may
e a disease course starting with lipid accumulation in the
ultivariable Associations Between E/A and Myocardial Triglycerid
Table 4 Multivariable Associations Between E/A and Myocard
E/A Bet
Model 1
Myocardial triglyceride content (%) 0.31 (0
Model 2 (Model 1  diabetic state)
Myocardial triglyceride content (%) 0.28 (0
T2DM/healthy subject 0.07 (0
Model 3 (Model 2  age)
Myocardial triglyceride content (%) 0.20 (0
T2DM/healthy subject 0.02 (0
Age (yrs) 0.02 (0
Model 4 (Model 3  heart rate)
Myocardial triglyceride content (%) 0.20 (0
T2DM/healthy subject 0.03 (0
Age (yrs) 0.02 (0
10% increase in heart rate (beats/min) 0.97 (1
Model 5 (Model 4  diastolic blood pressure)
Myocardial triglyceride content (%) 0.20 (0
T2DM/healthy subject 0.05 (0
Age (yrs) 0.02 (0
10% increase in heart rate (beats/min) 0.89 (1
Diastolic blood pressure (mm Hg) 0.01 (0
Model 6 (Model 3)
Association between E/A and myocardial triglyceride
content after adjusting for diabetic state, age,
and each of following variables
a. LV mass/volume ratio 0.19 (0
b. Visceral fat (ml) 0.19 (0
c. 10% increase in hepatic triglyceride content 0.20 (0
d. Fasting plasma glucose (mmol/l) 0.19 (0
e. Body mass index (kg/m2) 0.23 (0
2 for the respective models, that is, in Model 1, with E/A as dependent and myocardial triglycer
ndependent variables; in Model 3, myocardial triglyceride content, diabetic state, and age are inde
ndependent variables; in Model 5, myocardial triglyceride content, age, diabetic state, heart ra
re separately entered for adjustment and beta and p values for the association between myocard
he separate components of the model; †level of significance of the model.
CI  confidence interval; other abbreviations as in Table 2.yocardium, leading to diastolic dysfunction. In a later ttage of disease, global systolic function may be impaired, as
iastolic abnormalities are most commonly observed earlier
han systolic abnormalities (30).
Furthermore, in uncomplicated T2DM, visceral fat vol-
me, and hepatic triglyceride content were increased and
orrelated to myocardial triglyceride content after adjust-
ent for diabetic state. Our findings support the evidence
hat lipotoxic processes in cardiomyocytes constitute an
mportant mechanism underlying the epidemiologic associ-
tion between visceral adiposity, ectopic steatosis, and car-
iovascular disease (10,31,32).
In the present study design, we cannot establish a causal
elationship between increased myocardial triglyceride con-
ent and reduced LV function. We cannot discriminate if
yocardial triglyceride accumulation per se hampers myo-
ardial function due to a mechanical effect, the formation of
ardiotoxic intermediates, or by intervening in other mech-
nisms such as calcium handling. In addition, excluding
omen from the study limits the generalizability of the
resent study. Further studies need to be initiated to make
ntent
iglyceride Content
CI) p Value* r2 p Value†
0.18 0.001
0.15) 0.001
0.19 0.001
0.10) 0.003
.22) 0.32
0.42 0.001
0.04) 0.015
.15) 0.725
0.01) 0.001
0.46 0.001
0..04) 0.014
.10) 0.671
0.01) 0.001
0.14) 0.023
0.50 0.001
0.05) 0.009
.08) 0.487
0.01) 0.001
0.08) 0.032
0.001) 0.031
0.03) 0.017 0.47 0.001
0.02) 0.026 0.42 0.001
0.01) 0.036 0.42 0.001
0.02) 0.025 0.43 0.001
0.01) 0.033 0.44 0.001
tent as independent variable; in Model 2, myocardial triglyceride content and diabetic state are
nt variables; in Model 4, myocardial triglyceride content, diabetic state, age, and heart rate are
diastolic blood pressure are independent variables; in model 6 (a to e), the possible confounders
ceride content and E/A are displayed. *Level of significance for the association between E/A ande Co
ial Tr
a (95%
.48 to
.46 to
.07 to 0
.36 to
.10 to 0
.03 to
.35 to
.16 to 0
.03 to
.81 to
.35 to
.17 to 0
.03 to
.71 to
.02 to
.34 to
.35 to
.38 to
.36 to
.33 to
ide con
pende
te, and
ial triglyhese distinctions and to extend our findings to female
s
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ccumulation in the human diabetic heart, because in
nimal models, therapeutic interventions aiming at reduc-
ion of myocardial triglyceride accumulation due to dis-
urbed fatty acid metabolism have been shown to have
eneficial effects on myocardial function (7).
Furthermore, pioglitazone, a peroxisome proliferator-
ctivated receptor gamma agonist, which has the capacity to
ivert fat from nonadipose tissue to subcutaneous tissue, has
een shown to lower myocardial triglyceride content in
2DM patients on an insulin-based treatment regimen
33). Therefore, myocardial triglyceride content might be a
seful indicator of myocardial steatosis for predicting the
everity of diabetic cardiomyopathy and for evaluating the
ffects of antisteatotic therapy.
onclusions
yocardial triglyceride content is increased in uncompli-
ated T2DM and associated with impaired LV diastolic
unction, independently of age, BMI, heart rate, visceral fat,
nd diastolic blood pressure. Therefore, myocardial steatosis
ight be a useful indicator for predicting the severity of
iabetic cardiomyopathy and for evaluating the effects of
ntisteatotic therapy.
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